The Clinical Trial Risk Tool has been selected as a winner of the Plotly Dash Example Apps Challenge (2023), out of 25 amazing apps submitted by the Dash users community! The trial risk app is built on Plotly Dash, a front end graphical software package.
Thomas Wood from Fast Data Science will be presenting the tool in a webinar on 7 June 2023 which you can book here.
Thank you to all #PlotlyCommunity members who participated in the recent #Dash Example Apps Challenge, and congratulations to the winning submissions!
— Plotly (@plotlygraphs) May 22, 2023
🥇 Clinical Trial Risk Dash App by Thomas Wood
🥈 SARIMA Tuner by Gabriele Albini
🥉 Product Environmental Report Dash App by…
Meanwhile, we have an article published at Wood TA and McNair D. Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness [version 1; peer review: awaiting peer review]. Gates Open Res 2023, 7:56 (https://doi.org/10.12688/gatesopenres.14416.1).
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan Introduction The success of clinical studies relies heavily on proper financial planning and budgeting. These processes directly impact key factors such as project timelines, resource allocation, and compliance with regulatory requirements. The accurate forecasting of costs for clinical trials, however, is a highly complex and resource-intensive process. A study by the Tufts Center for the Study of Drug Development found that the average cost of developing a new drug is approximately $2.
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan Introduction Recent years have seen a substantial rise in oncology clinical trials, with annual growth exceeding 260 studies on average [1]. Despite this increase, these studies continue to be some of the most demanding and resource-intensive in clinical research. The combination of intensive monitoring, detailed assessment schedules, and highly specific eligibility criteria creates substantial operational challenges.
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan Introduction In recent years, the cost of conducting clinical trials has risen dramatically. This increase has posed a significant challenge for pharmaceutical companies, researchers, and healthcare innovators. According to a study published in Nature Reviews in 2017, the median cost of conducting a study was $3.4 million for phase I trials, $8.6 million for phase II trials, and $21.
